Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment

Lignende værker

• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  af: Huang, Yen-Hsiang, et al.
  Udgivet: (2021)
• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  af: Tseng, Jeng-Sen, et al.
  Udgivet: (2016)
• ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
  af: Chang, Gee-Chen, et al.
  Udgivet: (2020)
• Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
  af: Lee, Po-Hsin, et al.
  Udgivet: (2021)
• Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
  af: Hsu, Kuo-Hsuan, et al.
  Udgivet: (2021)